Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 06, 2022 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics to Present at the H.C. Wainwright BioConnect Conference

NORCROSS, Ga., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be...
November 15, 2021 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2021, and Provides Business Update

Board approves exploration of a Company-sponsored belapectin oncology program complementing our ongoing NASH cirrhosis program Leading oncology experts engaged to consult on strategic planning...
November 05, 2021 16:24 ET | Source: Galectin Therapeutics Inc.

UPDATE – Galectin Therapeutics to Present Six Scientific Abstracts at The Liver Meeting™ 2021, Hosted by the AASLD

New data regarding the mechanism of action of belapectin to inhibit galectin-3Unique pharmacokinetic profile of belapectin in patients with hepatic insufficiencyInnovating in Liver Cirrhosis:...
October 27, 2021 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Pharmaceuticals to Present Six Scientific Abstracts at The Liver Meeting™ 2021, Hosted by the AASLD

New data regarding the mechanism of action of belapectin to inhibit galectin-3Unique pharmacokinetic profile of belapectin in patients with hepatic insufficiencyInnovating in Liver Cirrhosis:...
October 05, 2021 15:39 ET | Source: Galectin Therapeutics Inc.

UPDATE: Galectin Therapeutics to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021

NORCROSS, Ga., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be...
September 09, 2021 09:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics, Inc. to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

NORCROSS, Ga., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the Company’s...